Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 133

1.

Association of cytokine and matrix metalloproteinase profiles with disease activity and function in ankylosing spondylitis.

Mattey DL, Packham JC, Nixon NB, Coates L, Creamer P, Hailwood S, Taylor GJ, Bhalla AK.

Arthritis Res Ther. 2012 May 28;14(3):R127. doi: 10.1186/ar3857.

2.

Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in ankylosing spondylitis: MMP-3 is a reproducibly sensitive and specific biomarker of disease activity.

Chen CH, Lin KC, Yu DT, Yang C, Huang F, Chen HA, Liang TH, Liao HT, Tsai CY, Wei JC, Chou CT.

Rheumatology (Oxford). 2006 Apr;45(4):414-20. Epub 2005 Nov 15.

PMID:
16287916
3.

Genetic polymorphisms of the matrix metalloproteinase-3 (MMP-3) and tissue inhibitors of matrix metalloproteinases-1 (TIMP-1) modulate the development of ankylosing spondylitis.

Wei JC, Lee HS, Chen WC, Shiu LJ, Yang SF, Wong RH.

Ann Rheum Dis. 2009 Nov;68(11):1781-6. doi: 10.1136/ard.2008.099481. Epub 2008 Nov 19.

PMID:
19019896
4.

Levels of serum matrix metalloproteinase-3 correlate with disease activity in the enthesitis-related arthritis category of juvenile idiopathic arthritis.

Viswanath V, Myles A, Dayal R, Aggarwal A.

J Rheumatol. 2011 Nov;38(11):2482-7. doi: 10.3899/jrheum.110352. Epub 2011 Sep 1.

PMID:
21885500
5.

Biomarkers of bone metabolism in ankylosing spondylitis in relation to osteoproliferation and osteoporosis.

Klingberg E, Nurkkala M, Carlsten H, Forsblad-d'Elia H.

J Rheumatol. 2014 Jul;41(7):1349-56. doi: 10.3899/jrheum.131199.

PMID:
24931960
6.

Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab.

Visvanathan S, Wagner C, Marini JC, Baker D, Gathany T, Han J, van der Heijde D, Braun J.

Ann Rheum Dis. 2008 Apr;67(4):511-7. Epub 2007 Jul 20.

7.

Role of matrix metalloproteinase-3 (MMP-3) and magnetic resonance imaging of sacroiliitis in assessing disease activity in ankylosing spondylitis.

Soliman E, Labib W, el-Tantawi G, Hamimy A, Alhadidy A, Aldawoudy A.

Rheumatol Int. 2012 Jun;32(6):1711-20. doi: 10.1007/s00296-011-1852-8. Epub 2011 Mar 24.

PMID:
21431945
8.

Osteopontin might be involved in bone remodelling rather than in inflammation in ankylosing spondylitis.

Choi ST, Kim JH, Kang EJ, Lee SW, Park MC, Park YB, Lee SK.

Rheumatology (Oxford). 2008 Dec;47(12):1775-9. doi: 10.1093/rheumatology/ken385. Epub 2008 Oct 14.

PMID:
18854347
9.

ASDAS, BASDAI and different treatment responses and their relation to biomarkers of inflammation, cartilage and bone turnover in patients with axial spondyloarthritis treated with TNFα inhibitors.

Pedersen SJ, Sørensen IJ, Garnero P, Johansen JS, Madsen OR, Tvede N, Hansen MS, Thamsborg G, Andersen LS, Majgaard O, Loft AG, Erlendsson J, Asmussen K, Jurik AG, Møller J, Hasselquist M, Mikkelsen D, Skjødt T, Lambert R, Hansen A, Østergaard M.

Ann Rheum Dis. 2011 Aug;70(8):1375-81. doi: 10.1136/ard.2010.138883. Epub 2011 May 8.

PMID:
21551511
10.

Changes of clinical response and bone biochemical markers in patients with ankylosing spondylitis taking etanercept.

Woo JH, Lee HJ, Sung IH, Kim TH.

J Rheumatol. 2007 Aug;34(8):1753-9. Epub 2007 Jun 15.

PMID:
17610317
11.

Effects of simvastatin withdrawal on serum matrix metalloproteinases in hypercholesterolaemic patients.

Huang CY, Wu TC, Lin WT, Leu HB, Lin CP, Lin SJ, Chen JW.

Eur J Clin Invest. 2006 Feb;36(2):76-84.

PMID:
16436088
12.

Matrix metalloproteinases as novel disease markers in Takayasu arteritis.

Matsuyama A, Sakai N, Ishigami M, Hiraoka H, Kashine S, Hirata A, Nakamura T, Yamashita S, Matsuzawa Y.

Circulation. 2003 Sep 23;108(12):1469-73. Epub 2003 Sep 2.

13.

Serum levels of matrix metalloproteinase 3 and macrophage colony-stimulating factor 1 correlate with disease activity in ankylosing spondylitis.

Yang C, Gu J, Rihl M, Baeten D, Huang F, Zhao M, Zhang H, Maksymowych WP, De Keyser F, Veys EM, Yu DT.

Arthritis Rheum. 2004 Oct 15;51(5):691-9.

14.

Increased matrix metalloproteinase-3 serum levels in rheumatic diseases: relationship with synovitis and steroid treatment.

Ribbens C, Martin y Porras M, Franchimont N, Kaiser MJ, Jaspar JM, Damas P, Houssiau FA, Malaise MG.

Ann Rheum Dis. 2002 Feb;61(2):161-6.

15.

Evaluation of serum paraoxonase and arylesterase activities in ankylosing spondylitis patients.

Erdem FH, Karatay S, Yildirim K, Kiziltunc A.

Clinics (Sao Paulo). 2010 Feb;65(2):175-9. doi: 10.1590/S1807-59322010000200009.

16.

Human leukocyte antigen-G in ankylosing spondylitis and the response after tumour necrosis factor-alpha blocker therapy.

Chen CH, Liao HT, Chen HA, Liu CH, Liang TH, Wang CT, Tsai CY, Chou CT.

Rheumatology (Oxford). 2010 Feb;49(2):264-70. doi: 10.1093/rheumatology/kep360. Epub 2009 Dec 11.

PMID:
20008091
17.

Association of serum interleukin-17 and interleukin-23 levels with disease activity in Chinese patients with ankylosing spondylitis.

Chen WS, Chang YS, Lin KC, Lai CC, Wang SH, Hsiao KH, Lee HT, Chen MH, Tsai CY, Chou CT.

J Chin Med Assoc. 2012 Jul;75(7):303-8. doi: 10.1016/j.jcma.2012.05.006. Epub 2012 Jul 6.

18.

Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis.

Lukas C, Landewé R, Sieper J, Dougados M, Davis J, Braun J, van der Linden S, van der Heijde D; Assessment of SpondyloArthritis international Society.

Ann Rheum Dis. 2009 Jan;68(1):18-24. doi: 10.1136/ard.2008.094870. Epub 2008 Jul 14.

PMID:
18625618
19.

Beneficial effects of adalimumab on biomarkers reflecting structural damage in patients with ankylosing spondylitis.

Maksymowych WP, Rahman P, Shojania K, Olszynski WP, Thomson GT, Ballal S, Wong RL, Inman RD; M03-606 Study Group.

J Rheumatol. 2008 Oct;35(10):2030-7. Epub 2008 Sep 1.

PMID:
18785308
20.

Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT).

van der Heijde D, Dijkmans B, Geusens P, Sieper J, DeWoody K, Williamson P, Braun J; Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study Group.

Arthritis Rheum. 2005 Feb;52(2):582-91.

Supplemental Content

Support Center